067080 — Dae Hwa Pharm Co Income Statement
0.000.00%
Last trade - 00:00
- KR₩178bn
- KR₩291bn
- KR₩141bn
- 27
- 30
- 28
- 14
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 114,610 | 109,346 | 117,159 | 131,912 | 141,359 |
Cost of Revenue | |||||
Gross Profit | 48,630 | 42,770 | 43,673 | 46,099 | 45,406 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 109,510 | 106,528 | 115,965 | 129,099 | 139,696 |
Operating Profit | 5,099 | 2,818 | 1,194 | 2,812 | 1,663 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 14,319 | -796 | 4,525 | 2,426 | -456 |
Provision for Income Taxes | |||||
Net Income After Taxes | 9,072 | -2,483 | 1,962 | 1,221 | -514 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 10,541 | -2,008 | 2,217 | 1,116 | -1,147 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 10,541 | -2,008 | 2,217 | 1,116 | -1,147 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 638 | -79.1 | 175 | 147 | -59.1 |
Dividends per Share |